The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Eli Lilly and Company (NYSE:LLY) is one of the Top 10 Stocks That Will Profit from AI. The company has recently introduced LillyPod, the pharmaceutical industry’s most powerful NVIDIA-powered supercomputer. Embedded with AI, Lillypod is part of a continuous learning system that accelerates drug discovery and development.

On May 12, 2026, Eli Lilly and Company (NYSE:LLY) announced late-phase trial results showing that Foundayo (orforglipron) and lower-dose Zepbound effectively maintain weight loss after patients switch from higher-dose injectables. The company’s ATTAIN-MAINTAIN study indicated that patients transitioning from Wegovy or Zepbound to oral Foundayo maintained most of their initial weight loss after one year.  Similarly, the SURMOUNT-MAINTAIN trial showed that reducing Zepbound to 5 mg or continuing at the maximum tolerated dose will result in durable long-term weight maintenance. These findings were published in The Lancet and Nature Medicine and point to new flexible options for chronic obesity management while minimizing weight regain during the transition from one treatment to another.

Previously, on May 6, 2026, Eli Lilly and Company (NYSE:LLY) announced an additional $4.5 billion investment in its Indiana manufacturing sites. This brings the company’s total state commitment to $21 billion since 2020. With this additional commitment, the company intends to support its evolving pipeline and anticipated demand for its medicines. Eli Lilly and Company (NYSE:LLY) also opened its first dedicated genetic medicine facility to support advanced therapies from research to commercial supply.

Eli Lilly and Company (NYSE:LLY) is a healthcare company with headquarters in Indiana. Founded in 1876, the company develops human pharmaceutical products across cardiometabolic health, oncology, and immunology.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Harvard University Stock Portfolio: Top 10 Stock Picks and 10 Best Battery Technology Stocks to Buy Now

Disclosure: None. Follow Insider Monkey on Google News.